ES2040339T3 - Procedimiento para preparar un granulo farmaceutico. - Google Patents

Procedimiento para preparar un granulo farmaceutico.

Info

Publication number
ES2040339T3
ES2040339T3 ES198888304007T ES88304007T ES2040339T3 ES 2040339 T3 ES2040339 T3 ES 2040339T3 ES 198888304007 T ES198888304007 T ES 198888304007T ES 88304007 T ES88304007 T ES 88304007T ES 2040339 T3 ES2040339 T3 ES 2040339T3
Authority
ES
Spain
Prior art keywords
preparing
procedure
pharmaceutical granule
cimetidine
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888304007T
Other languages
English (en)
Inventor
Kevin Edward Pearmain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline & French Laboratories Ltd
Original Assignee
Smith Kline & French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878710966A external-priority patent/GB8710966D0/en
Priority claimed from GB878710965A external-priority patent/GB8710965D0/en
Application filed by Smith Kline & French Laboratories Ltd filed Critical Smith Kline & French Laboratories Ltd
Application granted granted Critical
Publication of ES2040339T3 publication Critical patent/ES2040339T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L INVENCION PROPORCIONA UN PREPARADO FARMACEUTICO QUE CONTIENE CIMETIDINA DE 2-10% EN PESO EN RELACION A LA CIMETIDINA, DE UN COPOLIMERO DE METACRILATO DE DIMETILAMINOETILO Y ESTERES DE ACIDO METACRILICO NEUTROS. EL PREPARADO TIENE BUENAS CARACTERISTICAS DE PALATABILIDAD Y DE DISOLUCION.
ES198888304007T 1987-05-08 1988-05-04 Procedimiento para preparar un granulo farmaceutico. Expired - Lifetime ES2040339T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878710966A GB8710966D0 (en) 1987-05-08 1987-05-08 Pharmaceutical compositions
GB878710965A GB8710965D0 (en) 1987-05-08 1987-05-08 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ES2040339T3 true ES2040339T3 (es) 1993-10-16

Family

ID=26292225

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888304007T Expired - Lifetime ES2040339T3 (es) 1987-05-08 1988-05-04 Procedimiento para preparar un granulo farmaceutico.

Country Status (12)

Country Link
US (1) US5188839A (es)
EP (1) EP0290229B1 (es)
JP (1) JP2721219B2 (es)
KR (1) KR960011236B1 (es)
AU (1) AU602582B2 (es)
DE (1) DE3863963D1 (es)
ES (1) ES2040339T3 (es)
GB (1) GB2204489B (es)
GR (1) GR3002410T3 (es)
IE (1) IE61692B1 (es)
PT (1) PT87423B (es)
WO (1) WO1988008703A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
GB8710965D0 (en) * 1987-05-08 1987-06-10 Smith Kline French Lab Pharmaceutical compositions
US5230901A (en) * 1988-03-23 1993-07-27 Knoll Ag Sustained release tablet of a mixture of alginates and polyacrylates
DE3809764A1 (de) * 1988-03-23 1989-10-05 Knoll Ag Mischung aus alginaten und polyacrylaten und deren verwendung
EP0349103B1 (en) * 1988-05-04 1992-11-25 Smith Kline & French Laboratories Limited Chewable tablet
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
DE3931215C2 (de) * 1988-09-20 1998-07-16 Glaxo Group Ltd Pharmazeutische Präparate auf der Grundlage von Ranitidin
ZA919510B (en) * 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
DK0587744T3 (da) * 1991-05-28 2003-10-20 Mcneil Ppc Inc Tygbar sammensætning til frigørelse af et lægemiddel
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
EG20380A (en) * 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
ATE217789T1 (de) * 1992-06-04 2002-06-15 Smithkline Beecham Corp Angenehm schmeckende pharmazeutische zusammensetzungen
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
SE9600071D0 (sv) † 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6183775B1 (en) * 1996-05-13 2001-02-06 Novartis Consumer Health S.A. Buccal delivery system
CA2258159C (en) * 1996-06-14 2006-03-21 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly disintegrable tablet
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5989588A (en) * 1996-10-04 1999-11-23 Merck & Co., Inc. Methods and compositions for preventing and treating heartburn
AU728423B2 (en) * 1996-10-04 2001-01-11 Mcneil-Ppc, Inc. Methods and compositions for preventing and treating heartburn
FR2766089B1 (fr) † 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
IN186245B (es) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
JP2002529503A (ja) 1998-11-17 2002-09-10 ニトロメッド，インク． ニトロソ化及びニトロシル化ｈ２リセプターアンタゴニスト化合物及び組成物並びにその利用方法
FR2794979B1 (fr) * 1999-06-21 2001-07-27 Patrick Veret Une nouvelle formulation de comprime composee de lactose, sorbitol, stearate de magnesium
PT1276470E (pt) 2000-04-20 2007-08-13 Novartis Ag Composição de revestimento para dissimular o sabor
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
AU2003209673B2 (en) * 2002-03-08 2007-10-18 M/S. Ind-Swift Limited Tasteless directly compressible fast-dissolving complexes and pharmaceutical formulations thereof
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
ITMI20041255A1 (it) * 2004-06-22 2004-09-22 Univ Degli Studi Milano Sistemi microparticellari per somministrazione orale di sostanze biologicamente attive
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
AU2005299490C1 (en) 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US7776831B2 (en) 2006-02-01 2010-08-17 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
KR101765357B1 (ko) 2009-12-02 2017-08-04 아데어 파마수티컬스 에스.알.엘. 펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물
JP7611556B2 (ja) * 2020-05-28 2025-01-10 日医工株式会社 服用性、安定性等に優れた医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5840529B2 (ja) * 1975-09-29 1983-09-06 明治製菓株式会社 ケイコウヨウセイザイノセイホウ
JPS5513239A (en) * 1978-07-14 1980-01-30 Fujisawa Pharmaceut Co Ltd Fine particulate drug composition
JPS5567375A (en) * 1978-11-17 1980-05-21 Harunobu Miura Automatic washer
JPS56164122A (en) * 1980-05-21 1981-12-17 Fujimoto Seiyaku Kk Drug composition comprising cimetidine as main agent
JPS58201725A (ja) * 1982-05-19 1983-11-24 Eisai Co Ltd 褐変化防止組成物
EP0205336B1 (en) * 1985-06-11 1991-09-11 Teijin Limited Oral sustained release pharmaceutical preparation
FR2593065B1 (fr) * 1986-01-22 1988-09-09 Smith Kline French Lab Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation.
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
JPS63188621A (ja) * 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
GB8710965D0 (en) * 1987-05-08 1987-06-10 Smith Kline French Lab Pharmaceutical compositions

Also Published As

Publication number Publication date
EP0290229B1 (en) 1991-07-31
EP0290229A1 (en) 1988-11-09
DE3863963D1 (de) 1991-09-05
KR960011236B1 (ko) 1996-08-21
JPH01503385A (ja) 1989-11-16
KR890701101A (ko) 1989-12-19
GB8810477D0 (en) 1988-06-08
AU602582B2 (en) 1990-10-18
US5188839A (en) 1993-02-23
PT87423B (pt) 1992-09-30
JP2721219B2 (ja) 1998-03-04
GB2204489A (en) 1988-11-16
WO1988008703A1 (en) 1988-11-17
GR3002410T3 (en) 1992-12-30
GB2204489B (en) 1990-11-14
AU1714088A (en) 1988-12-06
PT87423A (pt) 1989-05-31
IE61692B1 (en) 1994-11-16
IE881368L (en) 1988-11-08

Similar Documents

Publication Publication Date Title
ES541521A0 (es) Un procedimiento para la preparacion de piridazinaminas.
ES2032450T3 (es) Un procedimiento para preparar acetaminofen secado por pulverizacion.
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
ES2052629T3 (es) Pirazolo(3,4-d)piridinas, procedimiento para su preparacion y utilizacion como medicamentos.
ES8407049A1 (es) Un procedimiento para la preparacion de compuestos biciclicos.
ES2084944T3 (es) Amidas terapeuticas.
ES2108255T3 (es) Sistema de disolvente destinado para ser incluido en capsulas.
ES2098140T3 (es) Liosferas que contienen gonadotropina.
ES2054716T3 (es) Bis-naftalimidas, su obtencion y empleo.
ES2040290T3 (es) Resinas cambiadoras de iones cargadas con derivados del acido quinoloncarboxilico, su preparacion y aplicacion.
ES2051678T1 (es) Derivados de 5-oxo-l-prolina y uso farmaceutico de los mismos.
MX9307974A (es) Nuevos derivados de acido hidroxiiminoalquilindolcarboxilico, su obtencion y uso.
IT1219892B (it) Derivati dell' acido furanuronico,loro preparazione e loro impiego come medicamenti
ATE2146T1 (de) Pyrido (2,1-b) chinazolinon-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
IT1255968B (it) Composizioni farmaceutiche contenenti acido ursodesossicolico
ES2037709T3 (es) Derivados heterociclicos de seis miembros de n,n'-diacilhidrazinas n'-sustituidas.
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES2088053T3 (es) Medicamento y empleo del mismo para el tratamiento de estados de excitacion y disfunciones nerviosas.
ES2066902T3 (es) Soluciones estables de analogos de rebecamicina y su preparacion.
ES2061530T3 (es) 9-amino-1,4-etano-1,2,3,4-tetrahidroacridina y compuestos afines, intermediarios y un procedimiento para la preparacion de los mismos y su uso como medicamentos.
ES2053535T3 (es) Derivados heterociclicos de cinco miembros de n,n'-diacilhidrazinas n' sustituidas.
IT8621112A0 (it) Derivati dell'acido tiazolidin-4-carbossilico adattivita' farmaceutica.
FR2515038B1 (fr) A titre de medicaments, certains derives de l'acide 4-phenyl 4-oxo 2-butenoique et compositions les renfermant
ATE139701T1 (de) Zusammensetzung zur herabsetzung der nebenwirkungen eines arzneimittels

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 290229

Country of ref document: ES